Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to medicaments containing as active principle at least one compound of formula:
• 6-phenyl-7H-imidazo [1,2-a] pyrazine-8-one has been described by DD DAVEY (J. Org. Chem., 52, 4379 (1987)) but no pharmacological property is mentioned for this compound.
• R-j represents a hydrogen atom or an alkyl or phenyl radical
• R2 represents (a) a phenyl radical, (b) a phenyl radical substituted by one or more substituents chosen from halogen atoms and alkyl, alkoxy, polyfluoroalkyl, polyfluoroalkoxy, phenyl, nitro or cyano radicals, (c) a radical naphthyl, (d) a naphthyl radical substituted by one or more substituents chosen from halogen atoms and alkyl, alkoxy, polyfluoroalkyl, polyfluoroalkoxy, phenyl, nitro or cyano radicals, (e) a 2-, 3- or 4 radical -pyridyle, (f) a 2-, 3- or 4-pyridyl radical substituted by one or more substituents chosen from halogen atoms and alkyl, alkoxy, polyfluoroalkyl, polyfluoroalkoxy, phenyl, nitro or cyano radicals, (g)
• alkyl and alkoxy radicals and portions contain 1 to 4 atoms carbon in a straight or branched chain and the halogen atoms are fluorine, chlorine, bromine and iodine.
• the new compounds of formula (I) can be prepared by dealkylation and dealkification of the derivatives of formula:
• alk represents an alkyl radical and Hal represents a halogen atom and, preferably, a bromine atom.
• This reaction is preferably carried out in the presence of imidazole, at a temperature between 100 and 200 ° C.
• and R 2 have the same meanings as in formula (I) and Hal represents a halogen atom, on a 1-alkylimidazole-2-carboxamide.
• This reaction is generally carried out in an inert solvent such as dimethylformamide and acetonitrile, at a temperature between 50 and 150 ° C.
• an inert solvent such as dimethylformamide and acetonitrile
• the 1-alkylimidazole-2-carboxamides can be obtained by adaptation or application of the method described by DD DAVEY, J. Org. Chem., 52, 4379 (1987).
• the derivatives of formula (III) are marketed or can be obtained by application or adaptation of the methods described by K. SCHANK, Chem. Ber., 102, 385 (1969); A. ARCORIA, J. Het. Chem., 12, 385 (1975), RM LAIRD and RE PARKER, J. Am. Chem. Soc., 83, 4277 (1961), JN CHATTERJEA, J. Indian Chem. Soc, 32, 265 (1955) and J. Indian Chem. Soc, 34, 347 (1957), K.
• the compounds of formula (I) can be purified by the usual known methods, for example by crystallization, chromatography or extraction.
• the compounds of formula (I) can optionally be converted into addition salts with a mineral or organic acid by the action of such an acid within an organic solvent such as an alcohol, a ketone, an ether or a solvent chlorine.
• organic solvent such as an alcohol, a ketone, an ether or a solvent chlorine.
• salts examples include addition salts with mineral or organic acids such as acetate, propionate, succinate, benzoate, fumarate, maleate, oxalate, methanesulfonate, isethionate, theophyllinacetate, salicylate, methylene-bis - ⁇ -oxynaphtoate, hydrochloride, sulfate, nitrate and phosphate.
• mineral or organic acids such as acetate, propionate, succinate, benzoate, fumarate, maleate, oxalate, methanesulfonate, isethionate, theophyllinacetate, salicylate, methylene-bis - ⁇ -oxynaphtoate, hydrochloride, sulfate, nitrate and phosphate.
• the compounds of formula (I) have interesting pharmacological properties. They are non-competitive antagonists of the N-methyl-D-aspartate receptor (NMDA) and, more particularly, they are ligands for the glycine modulator sites of the NMDA receptor.
• NMDA N-methyl-D-aspartate receptor
• 3,4-dichlorophenyl, 2-, 3- or 4-pyridyl or 2- or 3-furyl are also ⁇ -amino-3-hydroxy-5-methyl-8-isoxazolepropionic acid receptor antagonists (AMPA), also known as the quisqualate receptor.
• AMPA ⁇ -amino-3-hydroxy-5-methyl-8-isoxazolepropionic acid receptor antagonists
• These compounds are therefore useful for treating or preventing all ischemias (such as focal or global ischemia) consecutive to cerebrovascular accidents, cardiac arrest, hypotension, cerebral palsy, cardiac or pulmonary surgery or severe hypoglycemia. They are also useful in the treatment of effects due to anoxia, whether perinatal or consecutive to drowning, suffocation, CO poisoning or cerebro-spinal lesions. These compounds can also be used to treat or prevent the development of neurodegenerative diseases, HUNTINGTON's chorea, ALZHEIMER's disease, senile dementia, amyotrophic lateral sclerosis, atrophy olivo-pontocrissabelleuse and PARKINSON's disease.
• These compounds can also be used with respect to epileptogenic and / or convulsive manifestations, for the treatment of cerebral or spinal trauma, to combat poisoning due to toxins agonists of glutamatergic receptors, of anxiety (KEHNE et al. , Eur. J. Pharmacol., 193, 283 (1991), depression (TRULLAS et al., Eur. J. Pharmacol., 185, 1 (1990), schizophrenia (REYNOLDS, TIPS, 13, 116 ( 1992), as analgesics (DICKENSON et al., Neurosc.
• the affinity of the compounds of formula (I) for the glycine site linked to the NMDA receptor was determined by studying the antagonism of the specific binding of [3H] -DCKA on membranes of rat cerebral cortex according to the method described. by T. CANTON et al., J. Pharm. Pharmacol., 44, 812 (1992).
• the [ 3 H] -DCKA (20 nM) is incubated in the presence of 0.1 mg of proteins at 4 ° C. for 30 minutes in 50 mM HEPES buffer, pH 7.5.
• Nonspecific binding is determined in the presence of 1 mM glycine.
• the bound radioactivity is separated by filtration on Whatman GF / B filters.
• the inhibitory activity of these products is generally less than or equal to 100 ⁇ M.
• the affinity of the compounds of formula (I) vis-à-vis the AMPA receptor was determined by studying the antagonism of the specific binding of [ 3 H] - AMPA on membranes of rat cerebral cortex (HONORE et al. , Neu ⁇ roscience letters, 54, 27 (1985)).
• the [ 3 H] -AMPA is incubated in the presence of 0.2 mg of protein at 4 ° C for 30 minutes in KH P04 10mM buffer, KSCN 100 ⁇ M, pH7.5.
• the non-specific binding is determined in the presence of 1 mM L-glutamate.
• the bound radioactivity is separated by filtration on PHARMACIA filters (Printed Filtermate A).
• the inhibitory activity of these products is generally less than 100 ⁇ M.
• the compounds of formula (I) have a low toxicity.
• LD50 is greater than 50 mg / kg via the IP route in mice.
• a solution stirred and maintained under a nitrogen atmosphere of 4.5 g of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo bro ⁇ mure [1, 2-a] pyrazinium in 24 g imidazole is heated for 20 hours at 175 ° C, cooled to 100 ° C and then poured onto 180 g of a mixture of water and ice (50-50 by weight). The solid is separated by filtration, washed twice with 60 cm 3 in total of distilled water and dried under reduced pressure. The product obtained (2.8 g) is dissolved in 150 cm 3 of boiling ethanol and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 1 hour at a temperature in the region of 5 ° C.
• 1-Methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as follows: a stirred solution of 3.9 g of 2 -bromoacetophenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile is kept boiling for 20 hours and cooled to 15 ° C. The crystals are separated by filtration, washed with ethyl ether and dried under reduced pressure. 4.5 g of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1,2-a] pyrazinium are thus obtained.
• 1-methylimidazole-2-carboxamide can be prepared as described by D. D. DAVEY, J. Org. Chem., 52, 4379 (1987).
• Example 2 The procedure is as in Example 1 but using 4.5 g of 6- (3-chlorophenyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide and 20 g of imidazole.
• the crude product (2.8 g) is dissolved in 350 cm 3 of boiling methanol and the solution, supplemented with bleaching black, is filtered hot.
• the filter is washed twice with 150 cm 3 in total of boiling methanol, then the filtrate and the washing are combined, concentrated under reduced pressure (15 mm Hg; 2 kPa) at 40 ° C so as to reduce their volume to 50 cm. 3 and kept for 16 hours at a temperature close to 5 ° C.
• 6- (3-chlorophenyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 5.2 g of 2-bromo-3'-chloroaceto-phenone to 85% and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile.
• 6- (3-chlorophenyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium are thus obtained.
• 2-Bromo-3'-chloroacetophenone can be prepared as described by R. M. LAIRD and R. E. PARKER, J. Am. Chem. Soc., 83, 4277 (1961).
• Example 2 The procedure is as in Example 1 but using 5 g of 6- (4-chlorophenyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide and 24 g imidazole.
• the crude product (4.4 g) is recrystallized from 500 cm 3 of methanol and thus 1.7 g of 6- (4-chlorophenyl) -7H-imidazo [1, 2-a] pyrazine-8- are obtained. one melting at 300 ° C (decomposition).
• 6- (4-chlorophenyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 4.5 g of 2-bromo-4'-chloroacetophenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile. This gives 4.6 g of 6- (4-chlorophenyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide.
• EXAMPLE 4 The procedure is as in Example 1 but starting with 3.3 g of 1-methyl-6- (2-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide and 16 g of imidazole. The crude product (3.2 g) is recrystallized from 25 cm 3 of methanol and 1.15 g of 6- (2-methylphenyl) -7H- imidazo [1, 2-a] pyrazine-8-one are thus obtained. at 250 ° C.
• 1-methyl-6- (2-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 4.5 g of 2-bromo-2'-methylaceto-phenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile. 1.5 g of 1-methyl-6- (2-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium are thus obtained.
• 2-Bromo-2'-methylacetophenone can be prepared as described by J.N. CHATTERJEA, J. Indian Chem. Soc, 32, 265 (1955).
• Example 2 The procedure is as in Example 1 but starting with 3.3 g of 1-methyl-6- (3-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide and 15 g of imidazole.
• the crude product (2.1 g) is recrystallized from 135 cm 3 of methanol and 1.2 g of 6- (3-methylphenyl) -7H- imidazo [1, 2-a] pyrazine-8-one are thus obtained. at 287 ° C (decomposition).
• 1-methyl-6- (3-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 4.3 g of 2-bromo-3'-methylaceto- phenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile. 4.3 g of 1-methyl-6- (3-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide are thus obtained.
• 2-Bromo-3'-methylacetophenone can be prepared as described by J. N. CHATTERJEA, J. Indian Chem. Soc, 34, 347 (1957).
• Example 2 The procedure is as in Example 1 but starting with 3.9 g of 1-methyl-6- (4-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide and 18 g of imidazole.
• the crude product (3 g) is dissolved in 700 cm 3 of boiling methanol and the solution, added with bleaching black, is filtered hot.
• the filter is washed with 50 cm 3 of boiling methanol, then the filtrate and the washing are combined, concentrated under reduced pressure (15 mm Hg; 2 kPa) at 40 ° C so as to reduce their volume to 50 cm 3 and kept for 60 hours at a temperature close to 5 ° C.
• 1-methyl-6- (4-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 4.1 g of 2-bromo-4'-methylaceto-phenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile. 3.9 g of 1-methyl-6- (4-methylphenyl) -8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium are thus obtained.
• 2-bromo-4'-methylacetophenone can be prepared as described by K. YAMAGUCHI. and H. SHOJI., J. Pharm. Soc. Japan, 74, 20 (1954).
• EXAMPLE 7 The procedure is as in Example 1 but starting with 5.1 g of 1-methyl-6- (3-nitrophenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide and 24 g of imidazole. 1.4 g of crude product (out of the 3.2 g obtained in total) is chromatographed on 84 g of neutral silica gel (0.020-0.045 mm) contained in a column 3.1 cm in diameter, eluting under pressure with a mixture of ethyl acetate and methanol (90-10 by volume) and collecting 20 cm 3 fractions.
• Fractions 35 to 85 are concentrated to dryness under reduced pressure (15 mm Hg; 2 kPa) at 50 ° C.
• the product obtained (0.6 g) is dissolved in 5 cm 3 of boiling dimethylformamide and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with ice-cold dimethylformamide and with ice-cold ethanol and then dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C. 0.15 g of 6- (3-nitrophenyl) -7H-imidazo [1, 2-a] pyrazine-8-one is thus obtained, melting at 350 ° C.
• 1-methyl-6- (3-nitrophenyl) -8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide of 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 4.5 g of 2-bromo-3'-nitroaceto-phenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile. 5.1 g of 1-methyl-6- (3-nitrophenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium are thus obtained.
• 2-bromo-3'-nitroacetophenone can be prepared as described by M. I. SHEVCHUK and A. V. DOMBROVSKII, Zh. Obshch. Khim., 33, 1135 (1963).
• Example 2 The procedure is as in Example 1 but starting with 6 g of 1-methyl- 6- (4-nitrophenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide and 24 g imidazole.
• the crude product (4.5 g) is recrystallized from 50 cm 3 of dimethylformamide and 0.96 g of 6- (4-nitrophenyl) -7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at 400 ° C. (decomposition).
• 1-methyl-6- (4-nitrophenyl) -8-oxo-7,8-dihydro-imida- zo [1,2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide but from 4.6 g of 2-bromo-4'-nitroacetophenone and 2 g of 1-methylimidazoie-2-carboxamide in 60 cm 3 of acetonitrile. 6 g of 1-methyl-6- (4-nitrophenyl) -8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide are thus obtained.
• 2-Bromo-4'-nitroacetophenone can be prepared as described by M. I. SHEVCHUK and A. V. DOMBROVSKII, Zh. Obshch. Khim., 33, 1135 (1963).
• the crystals are separated by filtration, washed successively with 15 cm 3 of acetonitrile, 15 cm 3 of ethyl ether and dried under reduced pressure (15 mm Hg; 2 kPa) at 60 ° C.
• the product obtained (3.9 g) is heated for 24 hours at 175 ° C in 24 g of imidazole and the mixture, cooled to 100 ° C, is poured onto a mixture of 75 g of ice and 75 g distilled water.
• the insoluble material is separated by filtration, washed with 50 cm 3 of distilled water and dried under reduced pressure.
• the product obtained (1.65 g) is chromatographed on 96 g of neutral silica gel (0.020-0.045 mm) contained in a column 3.3 cm in diameter, eluting under pressure with a mixture of dichloromethane and methanol (93 -7 by volume) and collecting 3 successive fractions of 100 cm 3 > 150 cm 3 and 1850 cm 3 .
• the last fraction is concentrated to dryness under reduced pressure (15 mm Hg; 2 kPa) at 50 ° C.
• the product obtained (0.9 g) is dissolved in 30 cm 3 of boiling dimethylformamide and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed successively with 5 cm 3 of ice-cold dimethylformamide, twice with 20 cm 3 in total of distilled water and with 10 cm 3 of ethanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C. 0.65 g of 6- (3-cyanophenyl) -7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at 335 ° C (decomposition).
• a stirred solution of 4.3 g of 2-bromo-4'-cyanoacetophenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile is kept boiling for 6 hours and cooled to 15 °. vs.
• the crystals are separated by filtration, washed with 15 cm 3 of acetonitrile and dried under reduced pressure.
• the product obtained (4.9 g) is heated for 20 hours at 175 ° C in 25 g of imidazole and the mixture cooled to 100 ° C is poured onto 150 g of a mixture of water and ice (50- 50 by weight). The solid is separated by filtration, washed with 15 cm 3 of distilled water and dried under reduced pressure.
• the product obtained (4.2 g) is dissolved in 60 cm 3 of boiling dimethylformamide and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed successively with 10 cm 3 of ice-cold dimethylformamide, twice with 20 cm 3 in total of distilled water and then with 10 cm 3 of ice-cold ethanol and dried under reduced pressure (1 mm Hg; 0, 13 kPa) at 80 ° C.
• 1.45 g of 6- (4-cyanophenyl) -7H-imidazo [1, 2- a] pyrazine-8-one are thus obtained, melting at 356 ° C (decomposition).
• Example 2 The procedure is as in Example 1 but starting from 8.9 g of 1-methyl-8-oxo-6- (4-trifluoromethylphenyl) -7,8-dihydro-imidazo bromide [1, 2-a ] pyrazinium and 40 g imidazole.
• the crude product (5 g) is dissolved in 170 cm 3 of boiling ethanol and the solution, supplemented with bleaching black, is filtered hot and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with 25 cm 3 of a mixture of water and methanol (50-50 by volume) and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 70 ° C.
• 1-methyl-8-oxo-6- (4-trifluoromethylphenyl) -7,8-dihydro-imidazo [1,2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide but from 10.2 g of 2-bromo-4'-trifluorome- 80% thylacetophenone and 3.2 g of 1-methylimidazole-2-carboxamide in 100 cm 3 of acetonitrile. 8.9 g of 1-methyl-8-oxo-6- (4-trifluoromethylphenyl) -7,8-dihydro-imidazo [1, 2-a] pyrazinium- bromide are thus obtained.
• 2-Bromo-4'-trifluoromethylacetophenone can be prepared as described by W. T. CALDWELL and G. C. SCHWEIKER, J. Am. Chem. Soc, 75, 5884 (1953).
• Example 2 The procedure is as in Example 1 but starting with 1.9 g of 1-methyl-8-oxo-6- (4-trifluoromethoxyphenyl) -7,8-dihydro-imidazo bromide [1, 2-a ] pyrazinium and 9 g imidazole.
• the crude product (1.15 g) is chromatographed on 60 g of neutral silica gel (0.020-0.045 mm) contained in a column 2.9 cm in diameter, eluting under pressure with a mixture of dichloromethane and methanol (93-7 by volume) and collecting 15 cm 3 fractions.
• Fractions 12 to 24 are concentrated to dryness under reduced pressure (15 mm Hg; 2 kPa) at 50 ° C.
• the product obtained (0.5 g) is dissolved in 15 cm 3 of boiling isopropanol and the solution, supplemented with bleaching black, is filtered hot.
• the filter is washed with 5 cm 3 of boiling isopropanol, then the filtrate and the washing are combined, concentrated under reduced pressure (15 mm Hg; 2 kPa) at 40 ° C so as to reduce their volume to 5 cm 3 and stored for 16 hours at a temperature close to 5 ° C.
• the crystals are separated by filtration, washed with 2 cm 3 of ice-cold isopropanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C.
• 1-methyl-8-oxo-6- (4-trifluoromethoxyphenyl) -7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide but from 2 g of 2-bromo-4'-trifluoromethoxyoxyetophenone and 0.75 g of 1-methylimidazole-2-carboxamide in 25 cm 3 of acetonitrile. 1.9 g of 1-methyl-8-oxo 6- (4-trifluoromethoxyphenyl) -7,8-dihydro-imidazo [1,2-a] pyrazinium are thus obtained.
• 1-methyl-6- (4-methoxyphenyl) -8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation 1-methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide but from 4.5 g of 2-bromo-4'-methoxyaceous- tophenone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile. 5.4 g of 1-methyl-6- (4-methoxyphenyl) -8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium are thus obtained.
• the insoluble material is separated by filtration, washed twice with 20 cm 3 in total of distilled water and dried under reduced pressure.
• the product obtained (3.8 g) is dissolved in 300 cm 3 of boiling isopropanol and the solution, supplemented with bleaching black, is filtered hot.
• the filtrate is concentrated under reduced pressure (15 mm Hg; 2 kPa) at 40 ° C so as to reduce the volume to 75 cm 3 and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with 5 cm 3 of ice-cold isopropanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C.
• 2-bromo-2 ', 4'-dichloroacetophenone can be prepared as described in patent WO 91/09857.
• the insoluble material which appears is separated by filtration, washed twice with 20 cm 3 in total of distilled water and dried under reduced pressure.
• the product obtained (2.8 g) is dissolved in 250 cm 3 of boiling methanol and the solution, supplemented with bleaching black, is filtered hot and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with 5 cm 3 of ice-cold methanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C. 0.97 g of 6- (3,4-dichlorophenyl) -7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at 315 ° C.
• 2-bromo-3 ', 4'-dichloroacetophenone can be prepared as described by R. FUCHS, J. Am. Chem. Soc, 78, 5612 (1956).
• a stirred solution of 4.75 g of 2-bromo-2'-acetonaphtone and 2 g of 1-methylimidazole-2-carboxamide in 60 cm 3 of acetonitrile is kept boiling for 48 hours and cooled to 15 °. vs.
• the crystals are separated by filtration, washed with ethyl ether and dried under reduced pressure.
• the product obtained (5.45 g) is heated for 24 hours at 175 ° C in 24 g of imidazole and the mixture, cooled to 100 ° C, is poured onto a mixture of 75 g of ice and 75 g of distilled water.
• the insoluble material is separated by filtration, washed with 50 cm 3 of distilled water and dried under reduced pressure.
• the product obtained (5 g) is dissolved in 25 cm 3 of boiling dimethylformamide and the solution, supplemented with bleaching black, is filtered hot.
• the filter is washed twice with 20 cm 3 in total of boiling dimethylformamide, then the filtrate and the washing are combined and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed successively with 10 cm 3 of ice-cold dimethylformamide, with 10 cm 3 of distilled water and with 10 cm 3 of ice-cold ethanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) to 60 ° C.
• a stirred solution maintained under a nitrogen atmosphere of 11.6 g of 1-methyl-8-oxo-6- (2-pyridyl) -7,8-dihydro-imidazo [1, 2-a] pyra zinium bromide in 55 g of imidazole is heated for 6 hours at 175 ° C, cooled to 95 ° C, added with 50 cm 3 of ethanol, cooled to a temperature in the region of 20 ° C then added with 50 cm 3 of acetone. The solid is separated by filtration, washed with acetone and dried under reduced pressure.
• the product obtained (5.6 g) is suspended in 1200 cm 3 of boiling distilled water and the mixture, supplemented with bleaching black, is filtered hot then the filter is washed twice with 500 cm 3 in total of boiling distilled water. The filtrate and the washing are combined and stored for 30 minutes at a temperature in the region of 5 ° C. The crystals are separated by filtration, and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 80 ° C. 1.1 g of 6- (2-pyridyl) -7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at 305 ° C.
• 1-Methyl-8-oxo-6- (2-pyridyl) -7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as follows: a solution stirred and kept under an atmosphere of nitrogen of 29 g of 2-bromoacetylpyridine hydrobromide and 10 g of 1-methylimidazole-2-carboxamide in 300 cm 3 of dimethylformamide is heated for 30 hours to 120 ° C, cooled to a temperature in the region of 20 ° C and added of 60 cm 3 of ethyl ether. After cooling to 5 ° C, the crystals are separated by filtration, washed with 20 cm 3 of acetone and dried under reduced pressure. 11.5 g of 1-methyl-8-oxo-6- (2-pyridyl) -7,8-dihydro-imidazo [1, 2-a] pyra zinium bromide hydrobromide are thus obtained.
• 2-Bromoacetylpyridine hydrobromide can be prepared as described by K. SCHANK, Chem. Ber., 102, 385 (1969).
• a solution stirred and maintained under a nitrogen atmosphere of 4.5 g of 6- (2-furyl) -1-methyl-8-oxo-7,8-dihydro-imidazo bro ⁇ mure [1, 2-a] pyrazinium in 20 g of imidazole is heated for 6 hours at 175 ° C, cooled to 90 ° C, supplemented with 50 cm 3 of distilled water and then poured onto 100 cm 3 of distilled water. After cooling to a temperature in the region of 20 ° C., the solid is separated by filtration, washed with distilled water and dried under reduced pressure.
• the product obtained (2.5 g) is dissolved in 200 cm 3 of boiling ethanol and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 1 hour at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with 10 cm 3 of ice-cold ethanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 50 ° C.
• 1.1 g of 6- (2-furyl) -7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at 270 ° C.
• 6- (2-furyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide can be prepared as in Example 1 for the preparation of bromide 1 -methyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium but from 4.5 g of 2-bromoacetylfuran and 3 g of 1 -methylimida-zole-2 -carboxamide in 100 cm 3 of acetonitrile. 5.6 g of 6- (2-furyl) -1-methyl-8-oxo-7,8-dihydro-imidazo [1,2-a] pyrazinium bromide are thus obtained.
• 2-bromoacetylfuran can be prepared as described by A. ARCORIA, J. Het. Chem., 12, 385 (1975).
• a solution stirred and maintained under a nitrogen atmosphere of 11.2 g of 1,5-dimethyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium bromide in 50 g of imidazole is heated for 20 hours at 160 ° C and for 4 hours at 175 ° C, cooled to 100 ° C and then poured over 150 g of a mixture of water and ice (50-50 in weight).
• the mixture is extracted 6 times with 700 cm 3 in total of chloroform and the organic extracts are combined, dried over magnesium sulphate and concentrated to dryness under reduced pressure (15 mm Hg; 2kPa) at 35 ° C.
• the product obtained (14.7 g) is dissolved in 110 cm 3 of boiling isopropanol and the solution, supplemented with bleaching black, is filtered hot.
• the filter is washed with 20 cm 3 of boiling isopropanol, then the filtrate and the washing are combined, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed twice with 50 cm 3 in total of iced isopropanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C.
• the product obtained (6.5 g) is dissolved in 100 cm 3 of boiling isopropanol and the solution, supplemented with bleaching black, is filtered hot.
• the filter is washed twice with 50 cm 3 in total of boiling isopropanol, then the filtrate and the washing are combined, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed twice with 30 cm 3 in total of iced isopropanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C.
• 4 g are chromatographed on 250 g of neutral silica gel (0.020-0.045 mm) contained in a column of 4.4 cm in diameter, eluting under pressure with a mixture of dichloromethane and methanol (95-5 by volume) and collecting 60 cm 3 fractions.
• Fractions 34 to 59 are combined and concentrated to dryness under reduced pressure (15 mm Hg; 2 kPa) at 40 ° C.
• the product obtained (3.2 g) is dissolved in 90 cm 3 of boiling isopropanol and the solution, supplemented with bleaching black, is filtered hot.
• the filter is washed with 20 cm 3 of boiling isopropanol, then the filtrate and the washing are combined, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with 10 cm 3 of ice-cold isopropanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 60 ° C.
• 1,5-dimethyl-8-oxo-6-phenyl-7,8-dihydro-imidazo [1, 2-a] pyrazinium can be prepared as follows: a solution stirred and maintained under a nitrogen atmosphere of 22 , 5 g of 2-bromopropiophenone and 10 g of 1-methylimidazole-2-carboxamide in 300 cm 3 of dimethylformamide is heated for 10 hours at 115 ° C and then concentrated under reduced pressure (1 mm Hg; 0.13 kPa) to 70 ° C.
• a stirred solution of 8 g of 2-bromo-2-phenyl-acetophenone and 3 g of 1-methylimidazole-2-carboxamide in 90 cm 3 of acetonitrile is kept boiling for 20 hours and cooled to a neighboring temperature 20 ° C.
• the crystals are separated by filtration, washed with acetonitrile then with ethyl ether and dried under reduced pressure.
• the product obtained (3.3 g) is dissolved in 17 g of molten imidazole and the solution, maintained under a nitrogen atmosphere, is heated for 20 hours at 175 ° C, cooled to 100 ° C and then poured over 100 cm 3 distilled water.
• the solid is separated by filtration, washed twice with 20 cm 3 in total of distilled water and dried under reduced pressure.
• the product obtained (2 g) is dissolved in 100 cm 3 of boiling ethanol and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 1 hour at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed with 10 cm 3 of ice-cold ethanol and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 50 ° C.
• 1.1 g of 5,6-diphenyl-7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at 305 ° C.
• the solid is separated by filtration, washed with 30 cm 3 of distilled water and dried under reduced pressure.
• the product (4.36 g) is dissolved in 75 cm 3 of boiling dimethylformamide and the solution, supplemented with bleaching black, is filtered hot, cooled and stored for 16 hours at a temperature in the region of 5 ° C.
• the crystals are separated by filtration, washed twice with 30 cm 3 of distilled water and dried under reduced pressure (1 mm Hg; 0.13 kPa) at 45 ° C.
• 1.6 g of 6- (4-biphenyl) -7H-imidazo [1, 2-a] pyrazine-8-one are thus obtained, melting at a temperature above 260 ° C.
• the medicaments according to the invention consist of at least one compound of formula (I) in free form or in the form of a salt, in the pure state or in the form of a composition in which it is associated with any other product.
• pharmaceutically compatible which may be inert or physiologically active.
• the medicaments according to the invention can be used orally, parenterally, rectally or topically.
• compositions for oral administration tablets, pills, powders (gelatin capsules, capsules) or granules can be used.
• the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
• these compositions can also include substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a colorant, a coating (dragees) or a varnish.
• liquid compositions for oral administration it is possible to use solutions, suspensions, emulsions, syrups and pharmaceutically acceptable elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or l 'paraffin oil.
• inert diluents such as water, ethanol, glycerol, vegetable oils or l 'paraffin oil.
• These compositions may include substances other than diluents, for example wetting products, sweeteners, thickeners, flavorings or stabilizers.
• the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspen ⁇ sions or emulsions.
• solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable.
• These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of a compound. sterile solids which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
• compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.
• compositions for topical administration can be, for example, creams, lotions, eye drops, mouthwashes, nasal drops or aerosols.
• the compounds according to the invention are particularly useful for the treatment and / or prevention of conditions which require the administration of an AMPA receptor antagonist or of an NMDA receptor antagonist.
• These compounds are therefore useful for treating or preventing all ischemias (such as focal or global ischemia) consecutive to cerebrovascular accidents, cardiac arrest, hypotension, cerebral palsy, cardiac or pulmonary surgical intervention or severe hypoglycemia. . They are also useful in the treatment of effects due to anoxia, whether perinatal or following drowning, suffocation or CO poisoning or cerebrospinal damage.
• These compounds are also useful for treating or preventing the development of neurodegenerative diseases, HUNTINGTON chorea, ALZHEIMER disease, senile dementia, amyotrophic lateral sclerosis, olivo-pontocerebellar atrophy and Parkinson's disease.
• These compounds can also be used vis-à-vis epileptogenic and / or convulsive manifestations, for the treatment of cerebral or spinal traumas, to combat poisoning due to toxins agonists of glutamatergic receptors, of anxiety, of depression, schizophrenia, as analgesics, antianorexics, antimigraine, antiemetics and to treat poisonings by neurotoxins or other substances agonists of the receptor NMDA, as well as the neurological disorders associated with viral diseases such as AIDS, rabies, measles and tetanus. These compounds are also useful for preventing symptoms of abstinence drugs and alcohol and the inhibition of addiction and opioid dependence.
• the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 10 mg and 100 mg per day orally for an adult with unit doses ranging from 5 mg to 50 mg of active substance.
• the doctor will determine the appropriate dosage according to age, weight and all other factors specific to the subject to be treated.
• capsules containing 50 mg of active product having the following composition are prepared:
• Tablets containing 50 mg of active product having the following composition are prepared according to the usual technique:
• a solution for injection containing 10 mg of active product having the following composition is prepared:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9452533

Family Applications (1)

Country Status (7)

Cited By (47)

Citations (2)

• 1993
  • 1993-11-05 FR FR9313164A patent/FR2711993B1/fr not_active Expired - Fee Related
• 1994
  • 1994-11-01 ZA ZA948592A patent/ZA948592B/xx unknown
  • 1994-11-02 JP JP7513048A patent/JPH09504539A/ja active Pending
  • 1994-11-02 AU AU81097/94A patent/AU8109794A/en not_active Abandoned
  • 1994-11-02 EP EP95900182A patent/EP0726900A1/fr not_active Withdrawn
  • 1994-11-02 WO PCT/FR1994/001268 patent/WO1995012594A1/fr not_active Application Discontinuation
  • 1994-11-03 IL IL11152694A patent/IL111526A0/xx unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events